Videregen Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.01M

  • Investors
  • 11

Videregen General Information

Description

Developer of tissue-engineered regenerative therapies designed to address the chronic shortage of organs for transplantation. The company's programs are focused on the development of a portfolio of bioengineered therapeutics with a lead clinical indication targeting life-threatening complications following lung surgery and a lead preclinical development project focused on thymus-related diseases and disorders, enabling patients to increase quality and length of life and reduce healthcare costs.

Contact Information

Website
www.videregen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Nexus
  • Discovery Way University of Leeds
  • Leeds LS2 3AA
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
TMT, Life Sciences
Corporate Office
  • Nexus
  • Discovery Way University of Leeds
  • Leeds LS2 3AA
  • England, United Kingdom

Videregen Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Videregen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 04-Apr-2024 $1.01M Completed Pre-Clinical Trials
11. Grant 01-Oct-2022 Completed Pre-Clinical Trials
10. Grant 01-Nov-2021 Completed Pre-Clinical Trials
9. Later Stage VC 28-Apr-2021 Completed Pre-Clinical Trials
8. Grant 01-Jun-2020 Completed Pre-Clinical Trials
7. Later Stage VC 08-Aug-2019 Completed Pre-Clinical Trials
6. Grant 01-Nov-2018 Completed Startup
5. Grant 10-Dec-2015 Completed Startup
4. Early Stage VC 21-Sep-2015 $1.26M $3.37M Completed Startup
3. Early Stage VC 24-Jun-2014 $2.12M $2.12M Completed Startup
To view Videregen’s complete valuation and funding history, request access »

Videregen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 68,247 $0.012700 $31.75 $31.75 1x $31.75 26.41%
Ordinary 16,000 $0.012700 $28.58 $28.58 1x $28.58 6.19%
To view Videregen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Videregen Patents

  • 39

    Total Documents Applications and Grants

  • Total Patents Families

  • 31

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Videregen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190177680-A1 Bioreactors and methods for processing biological material Active 03-Aug-2016
EP-3494205-A1 Bioreactors and methods for processing biological material Pending 03-Aug-2016
US-11473048-B2 Bioreactors and methods for processing biological material Active 03-Aug-2016
JP-6953511-B2 Bioreactors and methods for processing biological materials Active 03-Aug-2016
ES-2882026-T3 Decellularizing tissue Active 21-Oct-2015 A61L27/3687
To view Videregen’s complete patent history, request access »

Videregen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Videregen Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
KCP Nominees Corporation Minority
Horizon 2020 SME Instrument Government
Deepbridge Capital Venture Capital Minority
Ruffena Capital Growth/Expansion Minority
Angel (individual) Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Videregen FAQs

  • When was Videregen founded?

    Videregen was founded in 2011.

  • Where is Videregen headquartered?

    Videregen is headquartered in Leeds, United Kingdom.

  • What is the size of Videregen?

    Videregen has 6 total employees.

  • What industry is Videregen in?

    Videregen’s primary industry is Biotechnology.

  • Is Videregen a private or public company?

    Videregen is a Private company.

  • What is the current valuation of Videregen?

    The current valuation of Videregen is .

  • What is Videregen’s current revenue?

    The current revenue for Videregen is .

  • How much funding has Videregen raised over time?

    Videregen has raised $8.36M.

  • Who are Videregen’s investors?

    KCP Nominees, Horizon 2020 SME Instrument, Deepbridge Capital, Ruffena Capital, and are 5 of 11 investors who have invested in Videregen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »